Egetis Therapeutics

Major Shareholding Notification • Nov 23, 2020

PRESS RELEASE PledPharma AB

Clarification regarding ownership changes in PledPharma

Stockholm, November 23, 2020. PledPharma AB (STO: PLED) today announced that company has been informed that the shareholders Cidro Förvaltning AB (Peter Lindell) and Nortal Investments AB (Staffan Persson) on 10 and 20 November 2020, respectively, have transferred PledPharma shares. The transfers have triggered obligations to submit major shareholder notifications since both shareholders in these entities have decreased their respective holdings to a level below 5 % of the total number of shares and votes. PledPharma therefore wishes to inform that both transfers have been done to insurance endowment policies associated with the respective sellers.

Nortal Investments AB (Staffan Persson) and Cidro Förvaltning AB (Peter Lindell) will fulfil their obligations to subscribe for shares in the on-going rights issue.

For further information, please contact:

Nicklas Westerholm, CEO Tel. +46 (0)73 354 20 62 nicklas.westerholm@pledpharma.se

The information was submitted for publication, through the agency of the contact persons set out above, at 2020-11-23, 14:00 CET.

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The drug candidate Aladote® is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote® has been granted Orphan Drug Designation in the US. Through the acquisition of Rare Thyroid Therapeutics (RTT), the clinical portfolio also includes Emcitate®, for the treatment of MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A pivotal Phase IIb/III early intervention study is planned to start in Q4 2020. Emcitate has been granted Orphan Drug Designation in the US and EU. The Phase III POLAR program for the drug candidate PledOx® was prematurely stopped in Q2 2020. Results from POLAR program will determine if further development of PledOx is warranted via strategic partnerships and is expected to be announced in Q4 2020. The company is planning for a name change to Egetis Therapeutics pending a resolution at the EGM on December 11, 2020.

PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see www.pledpharma.com.